ICU Medical (ICUI) Stock Forecast, Price Target & Predictions
ICUI Stock Forecast
ICU Medical stock forecast is as follows: an average price target of $135.00 (represents a -24.58% downside from ICUI’s last price of $179.00) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ICUI Price Target
The average price target for ICU Medical (ICUI) is $135.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $135.00 to $135.00. This represents a potential -24.58% downside from ICUI's last price of $179.00.
ICUI Analyst Ratings
According to 2 Wall Street analysts, ICU Medical's rating consensus is 'Buy'. The analyst rating breakdown for ICUI stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ICU Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 17, 2024 | Jayson Bedford | Raymond James | $135.00 | $117.44 | 14.96% | -24.58% |
| Aug 09, 2022 | - | Raymond James | $190.00 | $188.10 | 1.01% | 6.15% |
| Aug 08, 2022 | - | Raymond James | $208.00 | $179.63 | 15.79% | 16.20% |
| May 10, 2022 | - | Raymond James | $235.00 | $201.17 | 16.82% | 31.28% |
The latest ICU Medical stock forecast, released on Jun 17, 2024 by Jayson Bedford from Raymond James, set a price target of $135.00, which represents a 14.96% increase from the stock price at the time of the forecast ($117.44), and a -24.58% decrease from ICUI last price ($179.00).
ICU Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $135.00 | $135.00 |
| Last Closing Price | $179.00 | $179.00 | $179.00 |
| Upside/Downside | -100.00% | -24.58% | -24.58% |
In the current month, the average price target of ICU Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ICU Medical's last price of $179.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | Raymond James | Outperform | Outperform | Hold |
| Aug 08, 2024 | Raymond James | Outperform | Outperform | Hold |
| Jun 21, 2024 | Needham | - | Hold | Initialise |
| Aug 08, 2022 | Raymond James | Outperform | Outperform | Hold |
| May 10, 2022 | Raymond James | Outperform | Outperform | Hold |
| Feb 28, 2022 | Raymond James | Outperform | Outperform | Hold |
ICU Medical's last stock rating was published by Raymond James on Sep 12, 2024. The company gave ICUI a "Outperform" rating, the same as its previous rate.
ICU Medical Financial Forecast
ICU Medical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $587.86M | - | $549.31M | $568.65M | $578.01M | $597.86M | - | $543.12M | $340.52M | $336.06M | $321.68M | $318.05M | $320.45M | $318.57M | $303.38M | $328.61M | $315.52M | $307.47M |
| Avg Forecast | $635.19M | $624.82M | $628.07M | $599.25M | $615.30M | $599.14M | $607.52M | $579.49M | $589.52M | $570.02M | $556.64M | $552.25M | $562.98M | $565.75M | $565.20M | $561.13M | $578.77M | $565.00M | $559.93M | $553.17M | $319.90M | $314.30M | $305.87M | $300.90M | $295.33M | $284.70M | $276.70M | $296.30M | $295.70M | $291.17M |
| High Forecast | $644.41M | $633.89M | $637.19M | $607.95M | $624.23M | $607.84M | $616.34M | $587.91M | $598.08M | $578.17M | $564.73M | $560.27M | $566.10M | $573.97M | $573.41M | $569.28M | $587.17M | $573.21M | $559.93M | $555.14M | $321.04M | $315.42M | $306.96M | $301.97M | $296.39M | $285.72M | $277.69M | $297.36M | $296.76M | $292.21M |
| Low Forecast | $626.58M | $616.36M | $619.56M | $591.13M | $606.96M | $591.02M | $599.29M | $571.65M | $581.54M | $561.87M | $549.10M | $544.77M | $558.42M | $558.09M | $557.55M | $553.53M | $570.93M | $557.35M | $559.93M | $550.63M | $318.43M | $312.86M | $304.46M | $299.52M | $293.98M | $283.39M | $275.43M | $294.94M | $294.34M | $289.83M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | - | 0.97% | 1.01% | 1.00% | 1.06% | - | 0.98% | 1.06% | 1.07% | 1.05% | 1.06% | 1.09% | 1.12% | 1.10% | 1.11% | 1.07% | 1.06% |
ICU Medical's average Quarter revenue forecast for Mar 24 based on 1 analysts is $552.25M, with a low forecast of $544.77M, and a high forecast of $560.27M. ICUI's average Quarter revenue forecast represents a -6.06% decrease compared to the company's last Quarter revenue of $587.86M (Dec 23).
ICU Medical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-12.18M | - | $2.76M | $75.18M | $7.41M | $68.79M | - | $45.89M | $46.84M | $55.56M | $59.57M | $51.78M | $54.23M | $50.58M | $45.45M | $43.84M | $43.09M | $54.08M |
| Avg Forecast | $71.21M | $70.05M | $70.41M | $67.18M | $68.98M | $67.17M | $68.11M | $64.97M | $66.09M | $63.90M | $62.40M | $12.05M | $63.12M | $63.43M | $63.36M | $10.95M | $64.89M | $61.33M | $62.77M | $11.71M | $41.70M | $48.48M | $53.74M | $47.64M | $44.89M | $30.58M | $30.42M | $39.00M | $34.90M | $53.07M |
| High Forecast | $72.25M | $71.07M | $71.44M | $68.16M | $69.98M | $68.15M | $69.10M | $65.91M | $67.05M | $64.82M | $63.31M | $14.45M | $63.46M | $64.35M | $64.28M | $13.14M | $65.83M | $73.59M | $62.77M | $14.05M | $50.03M | $58.18M | $64.48M | $57.17M | $53.87M | $36.69M | $36.51M | $46.80M | $41.88M | $63.69M |
| Low Forecast | $70.25M | $69.10M | $69.46M | $66.27M | $68.05M | $66.26M | $67.19M | $64.09M | $65.20M | $62.99M | $61.56M | $9.64M | $62.60M | $62.57M | $62.51M | $8.76M | $64.01M | $49.06M | $62.77M | $9.37M | $33.36M | $38.78M | $42.99M | $38.11M | $35.91M | $24.46M | $24.34M | $31.20M | $27.92M | $42.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.19% | - | 0.04% | 6.87% | 0.11% | 1.12% | - | 3.92% | 1.12% | 1.15% | 1.11% | 1.09% | 1.21% | 1.65% | 1.49% | 1.12% | 1.23% | 1.02% |
1 analysts predict ICUI's average Quarter EBITDA for Sep 23 to be $63.43M, with a high of $64.35M and a low of $62.57M. This is 2198.05% upper than ICU Medical's previous annual EBITDA (Jun 23) of $2.76M.
ICU Medical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-17.15M | - | $-9.93M | $-9.81M | $-15.54M | $-13.21M | - | $-38.07M | $19.93M | $31.08M | $28.40M | $23.73M | $26.14M | $24.99M | $18.91M | $16.83M | $20.64M | $26.56M |
| Avg Forecast | $57.37M | $52.54M | $50.96M | $41.33M | $48.14M | $42.69M | $41.39M | $33.42M | $34.98M | $30.34M | $24.34M | $-38.27M | $29.09M | $33.78M | $39.03M | $-34.79M | $38.05M | $34.31M | $40.21M | $-37.21M | $17.74M | $27.12M | $25.62M | $21.83M | $21.64M | $15.11M | $12.66M | $14.98M | $16.72M | $26.07M |
| High Forecast | $58.45M | $53.53M | $51.92M | $42.11M | $49.04M | $43.49M | $42.17M | $34.05M | $35.64M | $32.07M | $24.80M | $-30.62M | $29.83M | $34.42M | $39.77M | $-27.83M | $38.77M | $41.17M | $40.21M | $-29.77M | $21.29M | $32.55M | $30.74M | $26.20M | $25.97M | $18.13M | $15.19M | $17.97M | $20.06M | $31.29M |
| Low Forecast | $56.36M | $51.62M | $50.06M | $40.60M | $47.29M | $41.94M | $40.66M | $32.83M | $34.36M | $28.62M | $23.92M | $-45.93M | $27.86M | $33.19M | $38.34M | $-41.75M | $37.38M | $27.45M | $40.21M | $-44.66M | $14.19M | $21.70M | $20.49M | $17.47M | $17.31M | $12.08M | $10.12M | $11.98M | $13.37M | $20.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.59% | - | -0.25% | 0.28% | -0.41% | -0.38% | - | 1.02% | 1.12% | 1.15% | 1.11% | 1.09% | 1.21% | 1.65% | 1.49% | 1.12% | 1.23% | 1.02% |
ICU Medical's average Quarter net income forecast for Mar 22 is $-37.21M, with a range of $-44.66M to $-29.77M. ICUI's average Quarter net income forecast represents a -286.76% decrease compared to the company's last Quarter net income of $19.93M (Dec 21).
ICU Medical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $154.62M | - | $150.90M | $152.57M | $142.93M | $153.45M | - | $153.21M | $81.46M | $74.81M | $73.92M | $72.39M | $73.55M | $70.85M | $67.24M | $72.31M | $70.65M | $65.88M |
| Avg Forecast | $152.16M | $149.67M | $150.45M | $143.55M | $147.39M | $143.52M | $145.53M | $138.82M | $141.22M | $136.55M | $133.34M | $154.04M | $134.86M | $135.52M | $135.39M | $140.03M | $138.64M | $82.58M | $134.13M | $149.77M | $72.52M | $65.28M | $66.68M | $66.60M | $60.89M | $42.84M | $45.01M | $64.32M | $57.21M | $64.66M |
| High Forecast | $154.37M | $151.85M | $152.64M | $145.63M | $149.53M | $145.61M | $147.64M | $140.83M | $143.27M | $138.50M | $135.28M | $184.84M | $135.61M | $137.49M | $137.36M | $168.04M | $140.66M | $99.10M | $134.13M | $179.72M | $87.02M | $78.34M | $80.02M | $79.92M | $73.06M | $51.40M | $54.01M | $77.18M | $68.66M | $77.59M |
| Low Forecast | $150.10M | $147.65M | $148.42M | $141.60M | $145.40M | $141.58M | $143.56M | $136.94M | $139.31M | $134.59M | $131.54M | $123.23M | $133.77M | $133.69M | $133.56M | $112.03M | $136.76M | $66.07M | $134.13M | $119.82M | $58.01M | $52.23M | $53.35M | $53.28M | $48.71M | $34.27M | $36.01M | $51.46M | $45.77M | $51.72M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | - | 1.11% | 1.09% | 1.03% | 1.86% | - | 1.02% | 1.12% | 1.15% | 1.11% | 1.09% | 1.21% | 1.65% | 1.49% | 1.12% | 1.23% | 1.02% |
ICU Medical's average Quarter SG&A projection for Mar 24 is $154.04M, based on 1 Wall Street analysts, with a range of $123.23M to $184.84M. The forecast indicates a -0.37% fall compared to ICUI last annual SG&A of $154.62M (Dec 23).
ICU Medical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 1 | 1 | 1 | 7 | 10 | 10 | 10 | 10 | 6 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.71 | - | $-0.41 | $-0.41 | $-0.65 | $-0.55 | - | $-1.61 | $0.94 | $1.47 | $1.34 | $1.12 | $1.24 | $1.19 | $0.91 | $0.81 | $1.00 | $1.29 |
| Avg Forecast | $2.35 | $2.15 | $2.09 | $1.69 | $1.97 | $1.75 | $1.70 | $1.37 | $1.43 | $1.24 | $1.00 | $0.82 | $1.19 | $1.39 | $1.60 | $1.43 | $1.56 | $1.46 | $1.66 | $1.80 | $1.64 | $1.80 | $1.64 | $1.50 | $1.51 | $1.31 | $1.24 | $1.63 | $1.63 | $1.62 |
| High Forecast | $2.40 | $2.19 | $2.13 | $1.73 | $2.01 | $1.78 | $1.73 | $1.40 | $1.46 | $1.31 | $1.02 | $0.84 | $1.22 | $1.41 | $1.63 | $1.45 | $1.59 | $1.49 | $1.66 | $1.81 | $1.65 | $1.80 | $1.65 | $1.51 | $1.52 | $1.31 | $1.25 | $1.63 | $1.64 | $1.62 |
| Low Forecast | $2.31 | $2.12 | $2.05 | $1.66 | $1.94 | $1.72 | $1.67 | $1.35 | $1.41 | $1.17 | $0.98 | $0.81 | $1.14 | $1.36 | $1.57 | $1.40 | $1.53 | $1.44 | $1.66 | $1.79 | $1.63 | $1.79 | $1.63 | $1.49 | $1.50 | $1.30 | $1.23 | $1.62 | $1.62 | $1.61 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.60% | - | -0.26% | -0.29% | -0.42% | -0.38% | - | -0.89% | 0.57% | 0.82% | 0.82% | 0.75% | 0.82% | 0.91% | 0.73% | 0.50% | 0.61% | 0.80% |
According to 0 Wall Street analysts, ICU Medical's projected average Quarter EPS for Mar 22 is $1.80, with a low estimate of $1.79 and a high estimate of $1.81. This represents a 91.49% increase compared to ICUI previous annual EPS of $0.94 (Dec 21).
ICU Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $110.53 | $298.00 | 169.61% | Buy |
| AKYA | Akoya Biosciences | $2.94 | $7.90 | 168.71% | Buy |
| ANGO | AngioDynamics | $7.64 | $17.00 | 122.51% | Buy |
| ATRC | AtriCure | $28.21 | $49.57 | 75.72% | Buy |
| XRAY | DENTSPLY SIRONA | $26.28 | $40.00 | 52.21% | Buy |
| HAE | Haemonetics | $76.09 | $104.33 | 37.11% | Buy |
| NVST | Envista | $19.41 | $23.83 | 22.77% | Hold |
| HOLX | Hologic | $81.15 | $78.92 | -2.75% | Buy |
| MMSI | Merit Medical Systems | $96.16 | $93.38 | -2.89% | Buy |
| ICUI | ICU Medical | $179.00 | $135.00 | -24.58% | Buy |
| ATR | AptarGroup | $152.28 | $100.00 | -34.33% | Buy |
ICUI Forecast FAQ
Is ICU Medical a good buy?
Yes, according to 2 Wall Street analysts, ICU Medical (ICUI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of ICUI's total ratings.
What is ICUI's price target?
ICU Medical (ICUI) average price target is $135 with a range of $135 to $135, implying a -24.58% from its last price of $179. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ICU Medical stock go up soon?
According to Wall Street analysts' prediction for ICUI stock, the company can go down by -24.58% (from the last price of $179 to the average price target of $135), down by -24.58% based on the highest stock price target, and down by -24.58% based on the lowest stock price target.
Can ICU Medical stock reach $300?
ICUI's average twelve months analyst stock price target of $135 does not support the claim that ICU Medical can reach $300 in the near future.
What are ICU Medical's analysts' financial forecasts?
ICU Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.4B (high $2.44B, low $2.37B), average EBITDA is $269.23M (high $273.14M, low $265.58M), average net income is $165.63M (high $168.76M, low $162.71M), average SG&A $575.26M (high $583.62M, low $567.47M), and average EPS is $6.79 (high $6.92, low $6.67). ICUI's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.49B (high $2.52B, low $2.45B), average EBITDA is $278.85M (high $282.9M, low $275.08M), average net income is $202.2M (high $206.01M, low $198.64M), average SG&A $595.83M (high $604.49M, low $587.76M), and average EPS is $8.29 (high $8.45, low $8.14).
Did the ICUI's actual financial results beat the analysts' financial forecasts?
Based on ICU Medical's last annual report (Dec 2023), the company's revenue was $2.26B, beating the average analysts forecast of $2.26B by 0.18%. Apple's EBITDA was $22.82M, missing the average prediction of $200.86M by -88.64%. The company's net income was $-29.655M, missing the average estimation of $67.11M by -144.19%. Apple's SG&A was $606.69M, beating the average forecast of $545.81M by 11.15%. Lastly, the company's EPS was $-1.23, missing the average prediction of $5.6 by -121.95%. In terms of the last quarterly report (Dec 2023), ICU Medical's revenue was $587.86M, beating the average analysts' forecast of $562.98M by 4.42%. The company's EBITDA was $-12.183M, missing the average prediction of $63.12M by -119.30%. ICU Medical's net income was $-17.147M, missing the average estimation of $29.09M by -158.95%. The company's SG&A was $154.62M, beating the average forecast of $134.86M by 14.65%. Lastly, the company's EPS was $-0.71, missing the average prediction of $1.19 by -159.54%